HEALTH

Centocor to End U.S. Trial of Flagship Drug: Centocor Inc. announced that it is halting the final round of U.S. trials for its onetime flagship drug Centoxin but hopes to restart sales in Europe. The termination of trials for the drug, used in the treatment of septic shock, followed Malvern, Pa.-based Centocor’s decision to suspend testing in January because of a rising number of deaths among those who received the treatment. The most recent testing marked the last stage of drug trials before the product maker was able to submit an application for approval to the Food and Drug Administration. Centocor plans to work with the FDA to design new U.S. trials that determine which patients can benefit most from the treatment. Meanwhile, the company said it will soon enter talks with European regulators to reinstate Centoxin.